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Summary
The study was conducted to determine the correlations
between serum concentration of arsenic (As) with
increased or decreased predisposition to breast and
ovarian cancer.
All subjects analyzed in the study were divided into
two groups.
The subjects from the first group were Polish women,
positive for at least one of three founder mutations in
BRCA1 gene dominating in Poland (5382insC, C61G,
4153delA). In the second group were Polish women, with
breast cancers, unselected but negative for BRCA1 gene
mutation. Persons with detected tumor were considered as
cases and the others were considered as controls. In the
case first group one case and two controls, and in the case
of second group one case and one control, were paired
regarding many criteria (e.g. age, family cancer history,
cigarettes smoking), adnexectomy to achieve the maxi-
mum of similarity between them.
Arsenic was quantitatively measured in diluted serum
samples by inductively coupled plasma mass spectrometry
(ICP-MS) using mass spectrometer (Elan DRC-e, Perki-
nElmer) in DRC mode with methane as a reaction gas, for
removing polyatomic interferences in measurement.
Arsenic gave statistically significant differences in the
disease risk when comparing the proportion of controls
and cases in a certain quartile with the same proportion
in the first quartile. Individuals classified in the second
(3.6 µg/l – 4.5 µg/l), third (4.5 µg/l – 5.7 µg/l) and fourth
quartile (5.7 µg/l – 58 µg/l) had a significantly higher risk
of breast cancer (OR=1.7, p=0.01; OR=1.25, p=0.007;
OR=1.4, p=0.04, respectively) than those in the first quar-
tile (1.1 µg/l – 3.6 µg/l) in BRCA1 gene mutation carriers.
In the second group surprisingly lower risk of breast
cancer was observed among individuals classified in the
second quartile (2.01 µg/l – 2.97 µg/l) in comparison
with fourth quartile (4.11 µg/l – 9.14 µg/l) (p=0.054,
OR=2.4).
Additionally, ratio between arsenic and selenium was
analyzed. For the first group the ratios with statistically
significant differences between quartiles in the disease risk
are shown in Table 1. In the second group there were no
statistically significant differences observed.
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Table 1 Ratios between analyzed elements and selenium
among BRCA1 mutation carriers
As/Se Cases (n=99) Controls (n=198) OR p-value
0.016 - 0.044[ 21(21,2%) 53(26,8%) 1.000 -
[0.044 - 0.058[ 21(21,2%) 53(26,8%) 1.000 0.163776
[0.058 - 0.072[ 31(31,3%) 43(21,7%) 1.819 0.000587
[0.072 - 0.14 26(26,3%) 49(24,7%) 1.339 0.005561
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